*** THIS IS A PRESS RELEASE ***
Cannabotech is advancing in the development of botanical medicine for cancer: It reports obtaining a worldwide exclusive license to use a unique fungus for the development and commercialization of products for the treatment of pancreatic and colon cancers
The studied fungus was found effective in killing pancreatic cancer cells and reducing the extent of cancerous tumors in animals; Cannabotech estimates it will present a prototype of the drug as early as the first half of 2023;
Herzliya, Israel – 2 January 2022 – Cannabotech, which develops, among other things, medical cannabis-based products and fungal extracts, reports it received exclusive use of a patent for the development of drugs based on the extract of Cyathus striatus fungus. The fungus is being researched in the laboratory of Professor Fouad Fares, an expert in molecular biology and cancer research at the Faculty of Natural Sciences at the University of Haifa.
According to the agreement signed between Cannabotech and Carmel, the economic company of the University of Haifa, Cannabotech will develop a botanical drug for pancreatic and colon cancers, based on a combination of cannabinoids from the cannabis plant with the fungus extract researched in Professor Fares’ laboratory, which has shown promising results and found to be effective in killing pancreatic and colon cancer cells, and reducing the extent of cancerous tumors in animals, without damaging healthy tissues.
Dr. Alex Weissman, an expert in organic chemistry and former director of R&D at the Chimagis Active Ingredients Factory (API), and Dr. Isaac Angel, an expert pharmacologist with more than 15 years of experience in leading drug development processes, will assist Cannabotech in the research process.
A few days ago, Cannabotech reported the results of a study according to which its CannaboBreast product for the treatment of breast cancer, based on a unique combination of cannabinoids and terpenes from the cannabis plant, combined with standard chemotherapy, resulted in an improvement of up to 6-fold in the killing of cancer cells compared to existing treatment (from 10% to 60% cancer cell mortality).
Cannabotech CEO Elhanan Shaked said: “Cannabotech continues to advance according to its business plan. Along with our preventative medicine products that are already available today, we are operating in the medium-long term in a variety of clinical trials, the most significant of which is the development of a botanical drug for cancer-based on a unique combination of cannabinoids with the Cyathus striatus fungus.”
Professor Fouad Fares said: “We are pleased with the results achieved so far in animals and the critical reduction in the extent of cancerous tumors and with improved cancer cells’ mortality. The collaboration with Cannabotech enables us to accelerate the research and development process.”
About Cannabotech:
Cannabotech is an Israeli biomedical company that develops botanical solutions for preventive medicine and integrative medicine. These solutions are based on combinations of active agents from the cannabis plant and fungi that work on two central systems in the human body: the endocannabinoid system and the immune system.
As part of the concept of integrative medicine, in the last two years, Cannabotech has been developing a series of 8 preparations based on unique combinations of botanicals from medical cannabis and fungus-based products, designed to help patients with cancer and chronic pain. Upon completion of their development, the company’s goal is to designate the products to be integrated into oncology patients’ existing treatment protocol.
At the same time, Cannabotech is working to develop a defined treatment protocol made available to physicians and technology for treatment customization.
*** END OF PRESS RELEASE **
We would like to remind you that by subscribing to the THE WEEKLY newsletter you are the first to learn about new and exciting cannabinoid. Subscribe today and get our exclusive discounts on Delta 8, Delta 9, Delta 10 THC, THC-P, THC-O, HHC, THCV and other hemp-derived THC products.
